LLY vs WFC: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Wells Fargo & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
Wells Fargo & Company · Financial Services
$86.12
+20.4% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
WFC has more upside to fair value
(+20.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
WFC |
| Current Price |
$1,183.72 |
$86.12 |
| Fair Value Estimate |
$1,208.00 |
$103.68 |
| Upside to Fair Value |
+2.1%
|
+20.4%
|
| Market Cap |
$1,114.8B |
$260.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.8x
|
15.6x
|
| Price / Sales |
14.0x
|
2.0x
|
| Price / FCF |
52.7x
|
13.7x
|
| Revenue Growth YoY |
+47.7%
|
+11.3%
|
| Gross Margin |
83.4%
|
64.5%
|
| Operating Margin |
49.7%
|
21.2%
|
| Return on Equity |
92.6%
|
12.6%
|
| Dividend Yield |
0.57% |
2.15% |
| FCF Yield |
1.9%
|
7.3%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Wells Fargo is a diversified U.S. bank with roughly 197,000 employees operating four segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The business quality is solid but not exceptional: trailing return on equity is 12.6%, TTM net margin is 17.5%, and revenue grew 11.3% year over year in the most recent quarter while…
Accumulation Zones
| Metric |
LLY |
WFC |
| Zone Low |
$906.00 |
$77.76 |
| Zone High |
$1,026.80 |
$88.13 |
| In Buy Zone? |
No
|
Yes
|